Stockscreener 앱 받기
42.49
1.58%
-0.68
시간 외 거래:
42.49
전일 마감가:
$43.17
열려 있는:
$43.04
하루 거래량:
134.33K
Relative Volume:
0.31
시가총액:
$2.28B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+17.54%
1개월 성능:
+4.84%
6개월 성능:
+318.62%
1년 성능:
+322.79%
1일 변동 폭
$41.67
$43.17
1주일 범위
$36.16
$44.60
52주 변동 폭
$5.83
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
명칭
Zenas Biopharma Inc
전화
857-271-2954
주소
852 WINTER STREET, SUITE 250, WALTHAM
ZBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
42.49 | 2.32B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | Wedbush | Outperform |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-16 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Citigroup | Buy |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
Zenas BioPharma : Corporate Presentation - marketscreener.com
Is Zenas BioPharma Inc. stock attractive after correctionFibonacci Extensions & Target Triple-Digit Stock Opportunities - Bollywood Helpline
Analysts' Revenue Estimates For Zenas BioPharma, Inc. (NASDAQ:ZBIO) Are Surging Higher - simplywall.st
Zenas BioPharma (NASDAQ:ZBIO) Hits New 52-Week HighWhat's Next? - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Trading 8.9% HigherShould You Buy? - MarketBeat
Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next - ts2.tech
Zenas Biopharma stock reaches all-time high of 41.67 USD - Investing.com
Zenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says - marketscreener.com
Wedbush Reiterates Outperform Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to NASDAQ Biotechnology Index - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2025-12-21 | Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation | NDAQ:ZBIO | Press Release - Stockhouse
How interest rate cuts could boost Zenas BioPharma Inc. stockRecession Risk & Weekly Hot Stock Watchlists - ulpravda.ru
Zenas BioPharma approves 2026 inducement plan - MSN
Can Zenas BioPharma Inc. stock reach $100 price target2025 Risk Factors & Short-Term High Return Ideas - Улправда
Why Zenas BioPharma Inc. stock remains on buy listsJuly 2025 Technicals & Stepwise Swing Trade Plans - Улправда
Winners Losers: What sentiment indicators say about Zenas BioPharma Inc. stock2025 Big Picture & Daily Entry Point Trade Alerts - Улправда
Growth Value: How interest rate cuts could boost Zenas BioPharma Inc. stockShare Buyback & Weekly High Return Stock Forecasts - Улправда
Zenas Biopharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Insider Trends: How interest rate cuts could boost Zenas BioPharma Inc. stock - Улправда
Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Is Zenas BioPharma Inc. stock resilient to inflationJuly 2025 Retail & Step-by-Step Trade Execution Guides - DonanımHaber
What insider trading reveals about Zenas BioPharma Inc. stockJuly 2025 Chart Watch & Low Risk Entry Point Guides - DonanımHaber
New Highs: How interest rate cuts could boost Zenas BioPharma Inc. stockTrade Risk Summary & Risk Controlled Stock Alerts - Улправда
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire
Earnings Report: Is Zenas BioPharma Inc stock a bargain at current levelsJuly 2025 Earnings & Free Community Supported Trade Ideas - moha.gov.vn
Orelabrutinib’s SLE Phase 2b Success Could Be A Game Changer For Zenas BioPharma (ZBIO) - Sahm
H.C. Wainwright reiterates Buy rating on Zenas Biopharma stock amid competitor setback - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Trading 6.7% HigherTime to Buy? - MarketBeat
Zenas BioPharma Shares Surge Amid Promising Drug Trials - TipRanks
Buy Rating Reaffirmed for Zenas BioPharma: Promising Orelabrutinib Developments and Autoimmune Platform Potential - TipRanks
Promising Developments in Zenas BioPharma’s Orelabrutinib Drive Buy Rating Amidst Competitive Advantage and Expected Share Price Upside - TipRanks
Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod - Indian Pharma Post
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Zenas BioPharma (ZBIO): Reassessing Valuation After Orelabrutinib’s Phase 2b Lupus Success and China Phase 3 Green Light - Yahoo Finance
Zenas BioPharma (ZBIO): Reassessing a Rich Valuation After Positive Orelabrutinib Lupus Trial Milestones - Sahm
Zenas BioPharma Approves 2026 Inducement Plan - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 9.9%Should You Sell? - MarketBeat
ZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How - GuruFocus
InnoCare Pharma achieves primary endpoint in Phase 2b study of orelabrutinib - TipRanks
Innocare Pharma announces achievement of primary endpoint in phase 2b study of orelabrutinib - marketscreener.com
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus - The Manila Times
Zenas Prepares For INDIGO Phase 3 Readout—Reinstating Buy Rating (ZBIO) - Seeking Alpha
Zenas BioPharma Says Partner InnoCare's Phase 2b Orelabrutinib Study in Systemic Lupus Erythematosus Meets Primary Endpoint - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
IgG4-related Disease Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht - The Globe and Mail
Is Zenas BioPharma’s (ZBIO) Royalty Deal Quietly Rewriting Its Late-Stage Risk Profile? - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Federated Hermes Inc. Boosts Stake in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas Biopharma Inc (ZBIO) 재무 분석
Zenas Biopharma Inc (ZBIO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.08%
0.21%
자본화:
|
볼륨(24시간):